Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | ATP4A | P20648 | 3/20 | 0.44 |
| ▸ | ATP4B | P51164 | 3/20 | 0.44 |
| ▸ | ATP1A1 | P05023 | 2/20 | 0.44 |
| ▸ | ATP1B1 | P05026 | 2/20 | 0.44 |
| ▸ | ATP1A3 | P13637 | 2/20 | 0.44 |
| ▸ | ATP1B2 | P14415 | 2/20 | 0.44 |
| ▸ | ATP1A2 | P50993 | 2/20 | 0.44 |
| ▸ | ATP1B3 | P54709 | 2/20 | 0.44 |
| ▸ | FXYD2 | P54710 | 2/20 | 0.44 |
| ▸ | ATP1A4 | Q13733 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | CYP2E1 | P05181 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9527448 | 0.93 | BRS3 (0.68) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6879158 | 0.89 | BRS3 (0.59) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6881219 | 0.88 | BRS3 (0.57) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6881774 | 0.87 | BRS3 (0.56) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6465866 | 0.87 | ATP4A (0.57) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6877051 | 0.85 | BRS3 (0.59) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL6872845 | 0.85 | CYP2C9 (0.57) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL9527112 | 0.83 | BRS3 (0.69) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL9527455 | 0.83 | CYP2D6 (0.46) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 | |
| Ufiprazole SCHEMBL662986 | 0.82 | BRS3 (0.84) | BRS3CYP2D6CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | ATOPIX THERAPEUTICS LTD (GB) | 2014-11-06 | — | — | US | disclosed |
| EP-2790696-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | Atopix Therapeutics Limited (GB) | 2014-10-22 | — | — | EP | disclosed |
| WO-2013088109-A1 | COMBINATION OF CRTH2 ANTAGONIST AND A PROTON PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS | OXAGEN LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | SOHNSTEARNS & STERN | 2004-12-23 | — | — | US | disclosed |
| EP-0166287-B1 | DIALKOXYRIDINES, PROCESS FOR THEIR PREPARATION, THEIR APPLICATION AND MEDICAMENTS CONTAINING THEM | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1989-08-23 | — | — | EP | disclosed |
| US-4758579-A | e.g. pantoprazole or pantoprazole sodium | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-07-19 | — | — | US | disclosed |
| EP-0166287-A1 | Dialkoxyridines, process for their preparation, their application and medicaments containing them | Byk Gulden Lomberg Chemische Fabrik GmbH (DE) | 1986-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040258621-A1 | Method of treating snoring and other obstructive breathing disorders | HRH2, HRH1, HRH4 | BRS3 56/4885CYP2D6 146/4885CYP2C9 1227/4885 |
| US-20140328861-A1 | Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis | HRH2, HRH1, HRH4 | BRS3 203/4885CYP2D6 2814/4885CYP2C9 2737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.